$7.47
+0.20 (+2.75%)
Open$7.31
Previous Close$7.27
Day High$7.51
Day Low$7.30
52W High$33.83
52W Low$5.67
Volume—
Avg Volume8.1K
Market Cap49.30M
P/E Ratio—
EPS$-7.08
SectorBiotechnology
Analyst Ratings
Buy
7 analysts
Price Target
+7.5% upside
Current
$7.47
$7.47
Target
$8.03
$8.03
$5.28
$8.03 avg
$9.44
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 12.19M | 11.47M | 10.10M |
| Net Income | 876.0K | 905.7K | 740.1K |
| Profit Margin | 7.2% | 7.9% | 7.3% |
| EBITDA | 1.90M | 1.88M | 1.67M |
| Free Cash Flow | 486.5K | 519.3K | 559.1K |
| Rev Growth | +7.7% | +14.6% | +19.0% |
| Debt/Equity | 1.27 | 1.35 | 1.37 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.46 | -0.54% | 70.2 | 443.23B |
| AMGN | Amgen Inc | $415.21 | -0.63% | 25.8 | 225.90B |
| GILD | Gilead Sciences Inc | $138.36 | +0.16% | — | 169.87B |
| VRTX | Vertex Pharmaceuticals Inc | $505.75 | -2.07% | 30.7 | 135.24B |
| REGN | Regeneron Pharmaceuticals | $803.48 | -0.31% | 19.0 | 82.16B |
| ALNY | Alnylam Pharmaceuticals Inc | $228.65 | +0.67% | 37.6 | 30.39B |